Sumitomo Mitsui Trust Holdings Inc. Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 161.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,203,780 shares of the company's stock after purchasing an additional 5,680,656 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned approximately 4.25% of Recursion Pharmaceuticals worth $90,749,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its holdings in Recursion Pharmaceuticals by 116.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company's stock worth $40,000 after purchasing an additional 2,817 shares during the last quarter. Amundi lifted its stake in Recursion Pharmaceuticals by 69.6% during the fourth quarter. Amundi now owns 7,189 shares of the company's stock worth $57,000 after purchasing an additional 2,949 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Recursion Pharmaceuticals by 25.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company's stock worth $77,000 after buying an additional 2,050 shares during the period. Private Advisor Group LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $79,000. Finally, GTS Securities LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $80,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded down $0.07 on Thursday, hitting $7.40. 2,860,086 shares of the stock were exchanged, compared to its average volume of 6,626,345. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The company has a market capitalization of $1.74 billion, a PE ratio of -4.77 and a beta of 0.76. The business's fifty day moving average is $10.79 and its 200 day moving average is $9.09.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The firm had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on RXRX shares. Needham & Company LLC restated a "buy" rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. TD Cowen initiated coverage on Recursion Pharmaceuticals in a report on Friday, January 26th. They set a "market perform" rating on the stock. Finally, KeyCorp lifted their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Monday, March 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $12.75.

Insider Activity

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $10.58, for a total transaction of $212,171.32. Following the transaction, the director now directly owns 7,324,364 shares of the company's stock, valued at approximately $77,491,771.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 48,272 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $9.22, for a total value of $445,067.84. Following the completion of the sale, the chief executive officer now directly owns 774,703 shares of the company's stock, valued at approximately $7,142,761.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Blake Borgeson sold 20,054 shares of the business's stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $10.58, for a total value of $212,171.32. Following the completion of the sale, the director now owns 7,324,364 shares in the company, valued at $77,491,771.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 376,272 shares of company stock worth $3,831,435. Insiders own 19.96% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.